

1 Title: **Management of Antipsychotics in Primary Care: Insights from Healthcare**

2 **Professionals and Policy Makers in the UK**

3 Short Title: **Antipsychotic Management in Primary Care**

4 Alan A. Woodall<sup>1,2</sup>, Aseel S. Abuzour<sup>3</sup>, Samantha A. Wilson<sup>4</sup>, Frances S. Mair<sup>5</sup>, Iain Buchan<sup>6</sup>,

5 Sally B. Sheard<sup>4</sup>, Paul Atkinson<sup>4</sup>, Dan W. Joyce<sup>6</sup>, Pyers Symon\*, Lauren E. Walker<sup>7</sup>

6

7 AW ORCID: [0000-0003-2933-0508](https://orcid.org/0000-0003-2933-0508)

8 AA ORCID: [0000-0002-4073-4346](https://orcid.org/0000-0002-4073-4346)

9 SW ORCID: [0000-0002-7959-052X](https://orcid.org/0000-0002-7959-052X)

10 FM ORCID: [0000-0001-9780-1135](https://orcid.org/0000-0001-9780-1135)

11 IB ORCID: [0000-0003-3392-1650](https://orcid.org/0000-0003-3392-1650)

12 SS ORCID: [0000-0001-8116-9120](https://orcid.org/0000-0001-8116-9120)

13 PA ORCID: [0000-0001-8740-6561](https://orcid.org/0000-0001-8740-6561)

14 DJ ORCID: [0000-0002-9433-5340](https://orcid.org/0000-0002-9433-5340)

15 LW ORCID: [0000-0002-3827-4387](https://orcid.org/0000-0002-3827-4387)

16

17 **Author Affiliations:**

18 <sup>1</sup>Department of General Practice and Mental Health, Institute of Population Health,

19 University of Liverpool, UK

20 <sup>2</sup>Powys Teaching Health Board, Bronllys Hospital, UK

21 <sup>3</sup>Unit for Ageing and Stroke Research, School of Medicine, University of Leeds, UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 <sup>4</sup>Department of Public Health, Policy and Systems, Institute of Population Health, University  
23 of Liverpool, UK

24 <sup>5</sup>General Practice & Primary Care, School of Health and Wellbeing, University of Glasgow, UK

25 <sup>6</sup>NIHR Mental Health Research for Innovation Centre, University of Liverpool, UK

26 <sup>7</sup>Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and  
27 Integrative Biology, University of Liverpool, UK

28 \*PS is public advisor (no ORCID ID; address withheld; contact via corresponding author)

29

## 30 **ABSTRACT**

31 **Introduction:** Antipsychotic medication is increasingly prescribed to patients with serious  
32 mental illness. Patients with serious mental illness often have cardiovascular and metabolic  
33 comorbidities, and antipsychotics independently increase the risk of cardiometabolic  
34 disease. Despite this, many patients prescribed antipsychotics are discharged to primary  
35 care without planned psychiatric review. We explore perceptions of healthcare  
36 professionals and managers/planners of policy regarding management of antipsychotics in  
37 primary care.

38 **Methods:** Qualitative study using semi-structured interviews with 11 general practitioners  
39 (GPs), 8 psychiatrists, and 11 managers/planners of policy in the United Kingdom. Interviews  
40 were studied using inductive thematic analysis.

41 **Results:** Respondents reported competency gaps that impaired ability to manage patients  
42 prescribed antipsychotic medications holistically, arising from inadequate postgraduate  
43 training and professional development. GPs lacked confidence to manage antipsychotic  
44 medications alone; psychiatrists lacked skills to address cardiometabolic risks and did not

45 perceive this as their role. Communication barriers, lack of integrated care records, limited  
46 psychology provision, lowered expectation of patients with serious mental illness by  
47 professionals, and pressure to discharge from hospital resulted in patients in primary care  
48 becoming 'trapped' on antipsychotics, inhibiting opportunities to deprescribe.  
49 Organisational and contractual barriers between organisations exacerbate this risk, with  
50 socioeconomic deprivation and lack of access to non-pharmacological alternatives driving  
51 overprescribing. GPs and psychiatrists voiced professional fears of being blamed if an event  
52 causing harm occurred after stopping an antipsychotic, which inhibited deprescribing. A  
53 range of actions to overcome these barriers were suggested.

54 **Conclusions:** People prescribed antipsychotics experience a fragmented health system and  
55 suboptimal care. Many simple steps could be taken to improve quality of care for this  
56 population but inadequate availability of non-pharmacological alternatives and  
57 socioeconomic factors increasing mental distress need key policy changes to improve the  
58 current situation.

59

## 60 INTRODUCTION

61 Psychiatrists usually prescribe antipsychotic medication (APM) to treat serious mental illness  
62 (SMI) such as schizophrenia and bipolar affective disorder. Despite treatment, patients with  
63 SMI die 10-20 years prematurely, mainly from cardiometabolic diseases and cancer [1-5]. In  
64 recent years, 'atypical' APMs are increasingly prescribed due to reports of fewer  
65 extrapyramidal effects [6] , but they confer increased risk of obesity, type-2 diabetes  
66 mellitus, and cardiovascular disease [5, 7], and require ongoing clinical monitoring of  
67 cardiometabolic risk factors to ameliorate these risks, including body mass index, blood

68 pressure, lipid and glucose levels and monitoring for QTc prolongation on electrocardiogram  
69 (ECG) [8-10]. While APM are licensed for SMI, increased prescribing for personality disorder  
70 [11], depression [12], anxiety [13] insomnia [14], dementia [15], learning disability [16] and  
71 autistic spectrum disorder [17] is occurring. Currently, in the UK, only quetiapine is licensed  
72 as a treatment for depression, and risperidone is licenced for short-term use to manage  
73 aggression in patients with moderate to severe Alzheimer’s dementia; all other uses are off-  
74 licence [18]. In some countries, such as Norway, APM are regularly initiated by GPs [19]. In  
75 the UK however, APM initiation is mainly undertaken by psychiatrists; traditionally, where  
76 the patient remains under secondary care (outpatient clinic or hospital care led by a  
77 psychiatrist), psychiatrists optimise APM, and GPs mainly monitor cardiometabolic risk [20,  
78 21]. Unfortunately, many patients with SMI who attend psychiatric appointments are less  
79 likely to attend their GP for physical health follow-up [20, 21]. Many international health  
80 systems, mainly designed to manage acute rather than chronic illness, struggle to provide  
81 continuity of care to patients with chronic mental illness [22]. Patients taking APM deemed  
82 stable from a psychiatric perspective, or who do not have psychotic illnesses, are often  
83 discharged by psychiatrists to be managed solely by GPs, which blurs this traditional division  
84 of care and potentially leaves gaps in integrated care for these patients [23]. APM  
85 prescribing is increasing [6]; approximately 32% of patients with SMI who are often  
86 prescribed APM long-term do not have specialist psychiatric reviews [24]. This study  
87 explores the management of patients taking APM discharged to primary care. We explored  
88 the views of healthcare professionals (HCPs) who deliver this care and managers/planners  
89 or directors of policy (MDPs) of the health organisations where APM prescribing is occurring  
90 in the UK. The aim of this study was to identify potential barriers and facilitators of holistic  
91 care for people taking APM and views on the causes of increasing APM prescribing.

92

## 93 **METHODS**

### 94 **Design and Setting**

95 Qualitative study to explore views of professionals and policymakers involved in care of  
96 patients prescribed APM in primary care, by conducting semi-structured interviews with  
97 participants recruited from the UK. The 'Consolidated criteria for reporting Qualitative  
98 Research' guided study design and analysis of results [25].

99

### 100 **Participants and Recruitment**

101 Participants were recruited from England, Scotland, and Wales between 1<sup>st</sup> July 2022 and  
102 March 31<sup>st</sup> 2023, and included GPs and psychiatrists; some held additional roles as service  
103 managers or policy directors. In addition to HCPs, NHS managers, government advisors and  
104 policy directors from stakeholders (e.g., mental health charities, Royal Colleges) were also  
105 invited. Purposive sampling identified potential participants, who were sent study  
106 information and an invite to participate. Up to three invites were sent; if no response was  
107 received, attempts to recruit ceased. Participants were briefed about the study with  
108 researchers and written consent obtained prior to interview. Participants could withdraw  
109 consent at any time, including after interview.

110

111

112

## 113 **Data Collection**

114 Semi-structured interviews were undertaken between July 2022 and May 2023, and basic  
115 details of participant characteristics (professional role, whether clinicians had postgraduate  
116 experience of psychiatry and general practice, and duration of UK professional registration)  
117 were obtained. Interview schedules were developed and refined by the team (see  
118 supplemental file 1). Interviews were conducted by AW (clinician in general practice and  
119 psychiatry with qualitative research experience) and explored views on management of  
120 APM prescribing, barriers to holistic care and causes of increasing APM prevalence in the  
121 population. Interviews were conducted via Microsoft Teams. Audio data was transcribed  
122 verbatim and anonymised; each participant was assigned a code, then recordings deleted.  
123 Transcripts were not provided to participants for checking; no withdrawal of consent  
124 occurred after interview. Data collection and analysis were undertaken concurrently.

125

## 126 **Data Analysis**

127 Interview transcripts were analysed using inductive thematic analysis, using Braun and  
128 Clarke's methodology [26] to determine themes by constant comparison and ensuring data  
129 saturation was reached. QSR NVivo® Windows (Version 1.6) was used to organise, code, and  
130 analyse transcripts. Transcripts were repeatedly re-read to familiarise researchers with the  
131 data. This was followed by generation of initial codes, identifying themes and subthemes,  
132 and refining these to ensure final theme definitions reflected meaning within the data. The  
133 iterative categorisation of data into themes and subthemes, and interpretation of the data  
134 were undertaken by the coding team (AW, AA, SW, LW) to ensure analytical rigour and  
135 plausibility.

136

## 137 Patient and Public Involvement

138 A public advisor (PS) provided input to protocol design, study progress, analysis, and  
139 interpretation of results.

140

## 141 Ethics statement

142 The study received ethical approval from the Health Research Authority (IRAS: 311503) via  
143 NHS Research Ethics Committee-06 (22/WA/0173) .

144

## 145 RESULTS

146 Table 1 shows characteristics of participants; due to the national role of some MDPs, certain  
147 identifiable characteristics have been withheld to protect their anonymity. Of 46 subjects  
148 approached (20 GPs, 13 psychiatrists, 13 MDPs), 30 subjects (11 GPs, 8 psychiatrists, and 11  
149 MDPs) consented to interviews, lasting between 21-58 minutes (mean 41 minutes).

150

151 **Table 1: Characteristics of participants**

152

Participant ID	Role	Sex	Postgraduate UK training experience in psychiatry and general practice?	Time on relevant UK professional register
GP-01	GP partner	Male	Yes	21 years
GP-02	Salaried GP	Male	Yes	22 years
GP-03	GP partner	Female	Yes	16 years
GP-04	Salaried GP	Male	Yes	16 years
GP-05	GP partner	Male	Yes	21 years
GP-06	GP partner	Male	No	32 years

GP-07	Salaried GP	Male	Yes	8 years
GP-08	GP partner	Female	Yes	21 years
GP-09	GP partner	Male	No	11 years
GP-10	GP partner	Female	Yes	20 years
GP-11	GP partner	Female	Yes	21 years
PSY-01	Consultant Psychiatrist	Male	No	19 years
PSY-02	Consultant Psychiatrist	Male	No	25 years
PSY-03	Associate Specialist in Psychiatry	Male	No	30 years
PSY-04	Consultant Nurse in Psychiatry (Responsible Clinician)	Male	No	27 years
PSY-05	Consultant Psychiatrist	Male	No	21 years
PSY-06	Consultant Psychiatrist	Female	No	17 years
PSY-07	Specialty doctor in Psychiatry	Male	No	10 years
PSY-08	Consultant Psychiatrist	Male	No	22 years
MDP-01	Former Educational advisor (psychiatry) to national postgraduate training committee and Royal College of Psychiatrists	Withheld	No (also a consultant psychiatrist)	Withheld
MDP-02	Policy Director, mental health charity	Withheld	N/A	N/A
MDP-03	Government advisor on mental health	Withheld	Withheld	Withheld
MDP-04	Former executive officer of Royal College of General Practitioners	Withheld	Yes (also a GP)	Withheld
MDP-05	Medical Director of Local Medical Committee for health region	Male	Yes (also a GP)	Withheld
MDP-06	Director of Mental Health Services for provider organisation	Withheld	Withheld	Withheld



MDP-07	Director of Primary Care for a provider organisation	Withheld	Withheld	Withheld
MDP-08	Chief Pharmacist for a provider organisation	Withheld	Withheld	Withheld
MDP-09	Medical Director for a provider organisation	Male	Yes (also a GP)	Withheld
MDP-10	Representative of General Practitioners Committee (British Medical Association)	Withheld	Yes (also a GP)	Withheld
MDP-11	Former executive officer of General Practitioner Committee of British Medical Association	Withheld	Yes (also a GP)	Withheld

153

154

155 Five themes emerged that affected APM management in primary care: (1) Confidence of

156 HCPs around holistic management of APM; (2) Service pressures ‘trapping’ patients on APM

157 in primary care; (3) Communication barriers between primary and secondary care; (4)

158 Lowered expectations of patients by HCPs; (5) Strategic factors, such as contractual

159 divisions between primary and secondary care, worsening socioeconomic inequality causing

160 mental distress, and medicolegal fears of HCPs, affected whether patients remain on APM.

161 Themes (with illustrative quotes) are discussed below, and additional supporting quotes are

162 available (see supplemental file 2). At the end of each theme, potential facilitators of

163 optimal care suggested by respondents are discussed, with suggested actions for clinicians

164 and MDPs at both local and national levels.

165

166 **1. Confidence of HCPs around holistic management of APM**

167 Holistic care of patients taking APMs requires HCPs trained to manage both mental and

168 physical health concerns. Both GPs and psychiatrists lacked confidence to address both

169 mental and physical health concerns holistically, with many patients facing fragmented care  
170 as a result, where focus was either primarily on mental health, or physical health, but rarely  
171 both. HCPs described inadequate postgraduate training and limited opportunity to retain  
172 skills after specialist qualification as contributing factors to their perceived competency  
173 gaps. Three subthemes emerged:

174

175 **(a) GPs were reluctant to manage APM without psychiatrist support**

176 Most GPs felt their training did not encompass APM management and therefore felt  
177 inadequately skilled to manage APM prescribing without psychiatrist support. At the same  
178 time, GPs were concerned that patients might lack confidence in their ability to advise on  
179 APMs appropriately:

180 *“I don't think that my [junior doctor psychiatric] training necessarily made me more*  
181 *confident in relation to antipsychotics.... I don't think I'm confident enough to do that*  
182 *without some input.” (GP-07)*

183 *“It's not just a GP thing...the patient might not have the confidence in us to do it*  
184 *either... They've often demanded to be referred to psychiatry, because the GP*  
185 *couldn't make them better... to be then told by the same GP 'well actually I'm going*  
186 *to stop your antipsychotic'- the patient may not have the confidence that stopping it*  
187 *will be OK.” (GP-11)*

188 Psychiatrists recognised GPs' reluctance to manage APM when patients were discharged to  
189 primary care, but some psychiatrists felt GPs should be able to manage APM:

190 *“Your average GP has excellent capabilities to manage someone on antipsychotics....*

191 *The thing I think they lack... would be the confidence to do so.” (PSY-01)*

192 Potential facilitators to help GPs manage more patients prescribed APM independently

193 included direct support from pharmacists, who would have additional training in psychiatric

194 medication, to support appropriate APM optimisation while remaining in primary care:

195 *“Psychiatry pharmacists are very easy to contact.... they tend to give detailed letters*

196 *as to...what you could do. There are alternatives. I wouldn't necessarily make a*

197 *decision straight away without just sending the pharmacists a quick letter to say,*

198 *“this is a situation what would your advice be” and they might say*

199 *“aripiprazole....and then you need to do x y z”. And that would probably give me*

200 *more confidence. I don't think I would just switch than myself because I don't*

201 *necessarily have the confidence or the knowledge to do that.” (GP-07)*

202

203 **(b) Psychiatrists were reluctant to address cardiometabolic risks**

204 Respondents felt psychiatrists often disregarded cardiometabolic risks. Psychiatrists

205 explained that they felt they lacked the necessary skills to enable them to adequately

206 address cardiometabolic risks, but there was also a reluctance in some to consider this

207 might be part of their role. Many respondents felt this meant a missed opportunity to

208 intervene in cardiometabolic risk for some patients, as they acknowledged many patients

209 with SMI might not attend for GP follow up as expected, and this puts them at greater risk

210 of suboptimal management and poorer long-term outcomes:

211 *“I received no training in general practice... that's never been part of my psychiatric*  
212 *training. The idea that I would comfortably manage hypertension or diabetes... I*  
213 *don't feel comfortable with it at all.” (PSY-07)*

214 *“It's all 'go and talk to your GP'... that's another step in the loop... and the patient*  
215 *often doesn't go.” (MDP-10)*

216 GPs understood psychiatrists' reluctance to initiate medications for cardiometabolic risks  
217 but criticised a lack of non-pharmacological interventions (e.g., referrals to dieticians or  
218 smoking cessation services), with the expectation that GPs would undertake all of these.  
219 Some also noted that psychiatrists rarely made changes to APM to ameliorate  
220 cardiometabolic risks, their focus being solely on addressing psychiatric issues:

221 *“There is...mention in some letters about us helping the patient control lifestyle*  
222 *factors... What I don't [see] is any evidence in letters that those referrals have been*  
223 *made by the psychiatric teams themselves.” (GP-11)*

224 *“Your focus tends to be on mental health...when you're seeing someone in their 20s*  
225 *[with] acute psychotic illness and their life is coming apart - you're focusing on that,*  
226 *and you are thinking 'they might die of heart disease when they're 60? If I get them*  
227 *to 60, I've done really well!' “(PSY-01).*

228 Respondents felt having contracted GP support embedded in mental health teams,  
229 particularly for inpatient units to manage physical health risks, would overcome some of  
230 psychiatrists' lack of confidence around physical health interventions, and ensure that  
231 patients had holistic care prior to discharge. Others thought non-medically qualified

232 assistants, such as health care support workers to co-ordinate and ensure physical health  
233 monitoring occurred, would be of help in community mental health teams:

234 *“Either we make primary care accessible to that group of people or we embed*  
235 *generalists within mental health services. And I think it's going to be probably easier*  
236 *to embed people with good general physical health monitoring and physical health*  
237 *intervention skills within mental health, because we know that our group of patients*  
238 *tend to be the most resistant and wouldn't necessarily present to a GP”.* (MDP-06)

239

240 **(c) Gaps for HCPs in postgraduate and post-speciality training**

241 HCPs reported inadequate training to manage both psychiatric and cardiometabolic aspects  
242 of APMs. While 14/16 (88%) GPs interviewed had undertaken postgraduate psychiatric  
243 training, no psychiatrist interviewed had any postgraduate training in general practice (Table  
244 1). This impaired mutual understanding of each other's specialty: some psychiatrists thought  
245 it was a requirement that all GPs undertook psychiatric postgraduate training, and this  
246 partially drove the expectation that, therefore, GPs could manage APMs. It was of note that  
247 no psychiatrist stated they would have benefitted from postgraduate experience in primary  
248 care. Respondents confirmed postgraduate GP training did not cover APM management:

249 *“I think [GP trainees] were... treated differently [to psychiatric trainees]. It was felt*  
250 *that they didn't need that sort of in-depth knowledge [around APM management].”*

251 (PSY-05)

252 *“I would have initially thought that GPs would have all had to have done some*  
253 *training in [psychiatry], so am I'm wrong in that? [interviewer explains some GPs*

254            *have no psychiatric placement] ... I'm actually shocked.... I had the impression that*  
255            *they had to do a stint in psychiatry.” (PSY-04)*

256    GPs were worried that other stakeholders wanted them to manage more patients on APM  
257    without appreciating the unsustainable volume of specialist secondary care work being  
258    transferred to GPs:

259            *“The special interest groups are saying, 'Well, actually, this is not complicated... if*  
260            *you do some online teaching for an hour then the GP should know enough'.... It's not*  
261            *possible, because we can't keep up to date with all the different antipsychotics... as*  
262            *well as keeping up to date with all the different specialities and their specialist*  
263            *medications.” (GP-11)*

264    Psychiatrists confirmed they had little postgraduate specialty training on cardiometabolic  
265    risks of APM and MDPs involved in training confirmed this gap in the psychiatric curriculum.  
266    One MDP (a former director of postgraduate psychiatric training) felt that psychiatric  
267    trainees should have some exposure to working in general medicine or primary care to  
268    improve their holistic skills and gain a better understanding of how primary care functions:

269            *“It doesn't seem to be built into the curriculum. I don't directly influence what's going*  
270            *on in the [Royal College of Psychiatrists] anymore... I don't know what it says in terms*  
271            *of speaking to physical health.... for] adult psychiatry trainees.... [we need] to give*  
272            *them more experience of working in.... primary care, or could be on an acute medical*  
273            *assessment unit... I think [it] would help.” (MDP-01)*

274    There was a concern by GPs and psychiatrists that psychiatric vocational training placements  
275    for GPs were often unsuitable to gain relevant psychiatric experience (e.g., GP trainees

276 placed in forensic hospital posts with a low turnover of acutely unwell patients) and felt  
277 there was little recognition by both relevant Royal Colleges (who oversee postgraduate  
278 curricula for medical graduates in the UK) that management of APM was increasingly falling  
279 to GPs, as more patients were discharged to primary care. Many felt that this needed to be  
280 addressed by improved curriculum design and better co-ordination between the Royal  
281 College of General Practitioners (RCGP) and Royal College of Psychiatrists (RCPsych). Others  
282 felt there needed to be attitudinal changes within the psychiatric profession, which had to  
283 be led by the RCPsych, to accept that physical health concerns, often arising from APM side  
284 effects, was their responsibility to deal with:

285 *If it's a sequelae from their medications, I think they should be training on looking at*  
286 *ECGs and looking for QTc abnormalities, management of diabetes and QRISK*  
287 *[cardiovascular risk assessment] - I think would be sensible. (MDP05)*

288 GPs felt continuous professional development (CPD) sessions with psychiatrists were  
289 needed, to look at holistic care of patients on APMs (with both specialities on an equal  
290 footing, rather than psychiatrists 'lecturing GPs on what they need to do'), reflecting the  
291 need for both specialities to develop strategies and shared protocols to improve integrated  
292 care:

293 *"I would love to see our [CPD] sessions return to in-person, face-to-face, group-based*  
294 *multidisciplinary sessions... And I would like that to be all inclusive across our health*  
295 *board. It's a brilliant opportunity that we've got to develop beyond primary care."*  
296 [MDP-09]

297

## 298 **2. Service pressures ‘trapping’ patients on antipsychotics in primary care**

299 Respondents felt service pressures had increased APM prescribing, with three main  
300 subthemes emerging. Many voiced concerns about difficulty obtaining psychological  
301 interventions for patients, which meant both GPs and psychiatrists often had no recourse  
302 but to prescribe APM to help patients cope, especially for patients with non-psychotic  
303 illnesses including personality disorder, anxiety, and insomnia. Psychiatrists explained they  
304 were often under pressure to quickly discharge patients back to primary care, and this also  
305 contributed to prescribing APM to enable this to happen. However, GPs were concerned  
306 that when cardiometabolic risks were accruing in patients secondary to APM, many  
307 psychiatrists were reluctant to accept referrals back to their service for medication reviews:

308

### 309 **(a) Limited psychology provision**

310 Respondents, particularly psychiatrists, felt limited psychology provision forced APM  
311 prescribing, often used in an off-licence manner that GPs were not aware of, as a ‘stop-gap’  
312 which was not best practice:

313 *“What do you do when someone is presenting as severely anxious, mood difficulties,*  
314 *not sleeping, incredibly chaotic: wait 18 months for therapy?... Do you simply adhere*  
315 *to NICE recommendations and say... ‘there's nothing I can do for you, you're going to*  
316 *have to wait 18 months, it doesn't matter how distressed you are - just deal with it?”*

317 (PSY-08)



318 It was felt that there needed to be more assistant psychologist posts to help manage  
319 psychological demand, due to the fact it takes 5-6 years to fully train a clinical psychologist  
320 and so few were available:

321 *“Some of these newer roles - the Clinical Associate in Applied Psychology, the ‘CAAPS’*  
322 *roles.... I don't want to call them the equivalent of physician associates, but they can*  
323 *work with people in the psychological model under supervision. They can do the*  
324 *psychology, the formulations, they can deliver the interventions with support and*  
325 *with supervision.” (MDP-01)*

326

327 **(b) Pressure to discharge patients to primary care**

328 Psychiatrists reported pressure from service managers to discharge patients, even those  
329 with SMI if they were stable from a psychiatric perspective, and especially those who did  
330 not have a recognised psychotic illness. As a result of this transfer of patients to primary  
331 care, many GPs felt patients discharged would be unlikely to ever stop taking APM:

332 *“There was a lot of pressure a few years ago on caseload cleansing, and there was*  
333 *[a] bizarre diagram handed out: a huge pressure to [put] your caseload into one of*  
334 *these four boxes.... the only ones we should be keeping were the ‘complex and*  
335 *unstable’.... and this is ridiculous... if I discharged [these patients] to primary care,*  
336 *they'd be back in within two weeks.” (PSY-01)*

337 Many potential facilitators to reduce pressure to discharge patients to primary care were  
338 raised by respondents. Managers felt the removal of numerical targets imposed by  
339 governments as a measure of efficiency was needed – the preference being to measure

340 quality of outcomes rather than numbers of patients seen - to reduce pressure on mental  
341 health teams to discharge patients. There was a recognition that many patients with chronic  
342 SMI should remain under psychiatric care, with varying degrees of input, but as a minimum,  
343 to have an annual review with a psychiatric specialist. GPs felt that proper shared-care  
344 prescribing agreements should be in place for all antipsychotic prescribing, and discharge to  
345 GPs only undertaken with mutual agreement by both services (MDP06):

346 *“It not really shared-care a lot of the time. So once a ‘shared-care’ is in place,*  
347 *secondary care often seems to think, they can then just discharge patients without*  
348 *any agreement... the problem is that don't tend to attach any funding to it. So, you*  
349 *don't end up having the ability to be able to employ a mental health nurse to do the*  
350 *antipsychotic reviews...I think the main difficulty is getting proper shared-care in*  
351 *place, with the funding was attached, and you've then got the resources to do it*  
352 *properly.” (MDP05)*

353

354 **(c) Difficulty to get psychiatric review for patients with cardiometabolic symptoms**

355 GPs reported difficulty obtaining psychiatric review when cardiometabolic risks developed in  
356 those patients who were discharged to their care on APM. Psychiatrists often advised ‘no  
357 change to APM’ due to pressure on their appointments, so the chance to address  
358 cardiometabolic risk (e.g., by a change of APM to one with lower propensity for side effects  
359 such as weight gain) was missed due to resource limitations, rather than a decision based on  
360 clinical need:

361 *“There's time pressure -if I've got someone stable and want to switch their*  
362 *antipsychotic, then I'll have to give them more clinic appointments.” (PSY-02)*

363 In addition to the suggestion for formal shared-care agreements for all APM use, other  
364 respondents suggested a formal mechanism for a 5-yearly specialist review of all patients  
365 taking APM long-term in primary care. There was some debate, however, as to which  
366 profession would be best placed to do these reviews, with suggestions including training  
367 GPs with a specialist interest in mental health, community psychiatric nurse prescribers, or  
368 pharmacists. Psychiatrists however, felt that it was unlikely these other professionals would  
369 have the confidence to undertake reviews to reduce or withdraw APM, so should ideally be  
370 undertaken by their own specialism:

371 *“For that to happen, it would need to be done by the person with the most well-*  
372 *developed sense of judgment of risk.... I think that would be a strong case to argue*  
373 *for it being a psychiatrist doing it.... You could get somebody else doing it, but if they*  
374 *were less confident taking somebody off medication is always a bit of a scary thing to*  
375 *do. And it is always kind of tempting not to, because then you know what risks are*  
376 *there in doing that? So, I would suggest it might be best for a psychiatrist to do it.”*  
377 (PSY-03)

378

### 379 **3. Communication barriers between primary and secondary care**

380 Respondents felt that inadequate communication, both written, verbal, and in terms of  
381 Information Technology (IT) access and integrated care, emerged as three subthemes which  
382 inhibited better integrated care of patients prescribed APMs. GPs relayed how they rarely

383 had clear written discharge plans around ongoing APM use and struggled to get to speak to  
384 psychiatrists directly for advice. Psychiatrists related how referrals they received often  
385 lacked sufficient information to help manage patients, often from GPs who did not know the  
386 patient. All respondents, including MDPs, highlighted the fragmented plurality of different IT  
387 systems in primary and secondary care holding electronic health records (EHRs) in service  
388 silos, making it difficult for teams to access all records to get a comprehensive overview of  
389 the patient journey:

390

391 **(a) Inadequate information in written handover**

392 HCPs mentioned inadequate information in psychiatrist's letters on APM indication,  
393 duration, and monitoring; GPs were often unaware when APM was prescribed 'off-licence'  
394 and felt any anticipatory advice given was mostly only when to increase an APM to avoid the  
395 need to refer back to a psychiatrist. This left GPs with little confidence to make changes to  
396 APM prescribing independently:

397 *"As someone who completes discharge summaries, I'm going to hold my hand up and*  
398 *say, we don't always include that... GPs get patients discharged on an antipsychotic*  
399 *when they're 23 and they're still on the same antipsychotic at 43" (PSY-01)*

400 Psychiatrists reported referral letters from GPs lacked detail and lack of personal knowledge  
401 of the patient in the letter inhibited care, often only being a brief computer-collated GP  
402 summary:

403           *“Referral quality can be variable depending on the experience of the GP, and their*  
404           *interest in mental health... sometimes we [have to] go back and ask for more*  
405           *information.”* (PSY-05)

406   Virtually all respondents felt that having standardised discharge and outpatient review  
407   templates that indicated not only the current treatment but clear information on indication,  
408   whether the APM was being used off-licence, intended duration, and suggested plan for  
409   switching, weaning and reduction when safe to do so, would help support GPs to make APM  
410   prescribing decisions, and that this should be performance managed as part of a shared care  
411   agreement; many felt the only focus was on initiation and dose titration, and this was  
412   insufficient to enable appropriate holistic care:

413           *“It would be useful if the [mental health team] said they're on this drug, which*  
414           *requires X, Y and Z monitoring, and we would expect them to stay on the drug for x*  
415           *length of time. And I think they should say what the indication is and that it's being*  
416           *used off-licence.”* (GP10)

417

418   **(b) Difficulties in verbal communication between primary and secondary care.**

419   GPs reported difficulties speaking to psychiatrists, with responses often from non-medical  
420   professionals unable to address their APM concerns, and psychiatrists felt GPs did not often  
421   know patients well enough to provide any useful context when they called to find out more  
422   about the patient:

423 *“You often find - no disrespect to those health care workers ...queries that we raise*  
424 *are dealt with by health care workers way below the level of training of a consultant*  
425 *psychiatrist.” (GP-11)*

426 *“Because of the nature of general practice, you [often cannot] talk to a GP that*  
427 *knows the patient personally... information that comes with the familiarity with the*  
428 *patient that can be difficult to access.” (PSY-07)*

429 Some colleagues felt that services such as ‘Consultant Connect’ [27] were helpful, where a  
430 GP could speak to a senior psychiatrist for advice, but because that consultant could be  
431 located anywhere in the UK and did not know the patient or have access to the patient  
432 medical record, this was often quite limited when needing to discuss medication  
433 optimisation. Others felt that a local ‘consultant of the day’ who could take calls from GPs  
434 would be more likely to improve decision making, as they would have EHR access to guide  
435 management more effectively and document the advice given in the EHR. Psychiatrists also  
436 felt direct telephone numbers to GPs would improve communication. An indirect, but  
437 related benefit of joint CPD training was also mentioned, in that teams would get to know  
438 each other personally, which would improve mutual trust, problem-solving, and  
439 communication:

440 *“In [English Region], we developed a 'psychiatrist of the day' who would simply take*  
441 *calls from GP's, and it was amazing: the upskilling that results from that. The value of*  
442 *a local connection is twofold: One is, as a GP, I can seek advice about altering some*  
443 *of these medications, or whether or not they need referral right now.? Is there*  
444 *something else I can be doing with them? But two, also the 'psychiatrist of the day'*  
445 *gets to pick up what are the issues going on out there?' What's the common themes*

446 *that perhaps we could do something about? Do we need an education event, or a*  
447 *change to a pathway?” (MDP-09)*

448

449 **(c) Poor integration of IT systems used in health services**

450 Respondents highlighted that suboptimal IT systems inhibit HCP ability to manage patients  
451 holistically, partly due to separate EHR systems commissioned by and used in primary and  
452 secondary care services. HCPs often reported inability to view EHRs, resulting in wasted time  
453 seeking information:

454 *“The hospital will have one electronic system, and the GP will have a second*  
455 *electronic system. And then psychiatry has a third, even more separate, difficult to*  
456 *access system, which some people have viewable access to, but not editable access.”*  
457 (GP-07)

458 All respondents felt that improved access to shared records, utilising a common EHR system  
459 across primary and secondary care, would improve integrated care. Many would like the  
460 ability to add medications and have access to write into a common EHR, to avoid duplication  
461 of effort, and ensure that all professionals were fully up to date with patient care.

462 Respondents recognised that patient confidentiality needed to be protected, but some felt  
463 that an overemphasis on patient confidentiality, and having multiple EHR systems across the  
464 health service, led to fragmentation of clinical records that impaired patient care, leading to  
465 potential harm:

466 *“It is in every scenario - that kind of holy grail of the shared care record, it would sort*  
467 *it all out, it would solve it all.” (GP08)*

468

469 **4. HCPs have low expectations of patients taking APM**

470 It became apparent that some HCPs had low expectations of patients with SMI. They found  
471 them difficult to engage with therapeutically and described patients often missing  
472 appointments, causing frustration for staff trying to help them. HCPs felt this was often due  
473 to lack of motivation in the patient group. Other HCPs, however, felt that these patients  
474 were disadvantaged by the health system, often faced discrimination, and were given  
475 insufficient information on APM use to enable informed consent. This drove some HCPs to  
476 act as advocates for their patients:

477 *“They are not people who ask for help...they're beaten down by the system as well,*  
478 *and they accept their lot is just s\*\*\*, and ‘that’s just the norm for me’.... “They are*  
479 *seen to be a lost cause.... ‘Oh, they will never give up smoking, so there’s no point in*  
480 *me asking’.... And not only that, but it’s also their own fault - it’s the opposite of the*  
481 *truth, isn’t it really...They respond well to having someone who is interested in them...*  
482 *I’m not sure I make a massive difference... we’re there to pick stuff up when things go*  
483 *wrong, and start metformin when they inevitably become diabetic, or write the death*  
484 *certificate when they die young. You know, it feels a bit depressing to just verbalize*  
485 *it.” (GP-08)*

486 Many HCPs felt that tackling lowered expectations towards patients with SMI was  
487 challenging, and this mirrored societal attitudes. However, one MDP who represented  
488 patients from a mental health charity, did report that they felt GPs who had undertaken  
489 psychiatric training were more likely to be able to challenge and act as advocates for



490 patients, and that postgraduate psychiatric training should be mandated in the GP training  
491 programme:

492 *“I think with GP training, you maybe get one opportunity to spend time on a mental*  
493 *health ward, and I know from speaking to GPs, that those GP's that have done that*  
494 *understand the system better in terms of referrals... they are better able to challenge*  
495 *it and to be an advocate on behalf of their patients.” (MDP02)*

496

#### 497 **5. Strategic factors affecting APM prescribing in primary care**

498 Participants identified multiple professional and organisational constraints acting as barriers  
499 to optimise APMs. Three main subthemes emerged; the first subtheme focussed on the  
500 difficulties with the contractual split between primary and secondary care, with the UK GP  
501 General Medical Services (GMS) contract and narrow criteria for patient inclusion on the  
502 Quality and Outcomes Framework (QOF) mental health register, meant many patients now  
503 prescribed APM in primary care for non-psychotic illness were not being monitored  
504 effectively. Organisational competition and ‘protectionism’ for resources were mentioned,  
505 meaning patients could be disadvantaged by siloed care largely dictated by organisational  
506 budgetary constraints. A second theme centred around socioeconomic deprivation and  
507 medicalisation of distress driving APM use. A final theme described the fear many HCPs had  
508 around stopping or changing APMs in case an adverse event occurred that would render  
509 them liable to ‘societal blame’ or censure by regulatory bodies:

510

511

512 **(a) Contractual divisions between primary and secondary care**

513 Psychiatrists and MDPs felt the UK General Medical Services (GMS) GP contract structure  
514 inhibited shared care:

515 *“Sometimes it's the GMS contractual issues... that constant argument around "I'm*  
516 *not going to do this unless [GPs] get paid for it". Those sorts of issues really need to*  
517 *be addressed... sometimes we forget there's a patient at the end of all these*  
518 *decisions.”* (MDP-08)

519 The Quality and Outcomes Framework (QOF) in the UK GMS contract incentivises GPs to  
520 monitor physical health risks for patients with SMI, but incentives have been largely  
521 abolished in GMS contract revisions in Wales and Scotland; GPs felt this would deter  
522 ongoing monitoring. Many were concerned the QOF ‘mental health register’ criteria, being  
523 focussed almost exclusively on psychotic illness such as schizophrenia or bipolar affective  
524 disorder, did not capture all patients prescribed APM, so there was a risk many patients  
525 were not reviewed comprehensively:

526 *“In England, we still have the [QOF] mental health register.... but it doesn't pick up*  
527 *people who've got a personality disorder.”* (GP-04)

528 Respondents reported tensions between organisations contributed to protectionism that  
529 impaired care. A former Royal College officer reported conflicts of interest between  
530 representing members’ interests, and serving patients:

531 *“There is a real tension between being a member's organization that needs to deliver*  
532 *for its members' interests, and doing the right thing..., I was there representing*  
533 *[Royal College] ...we can see what the right thing is to do, but as membership*

534 *organizations, we have to protect the needs of our members. So, you would not*  
535 *expect the Royal College of GPs to meet with the Royal College of Psychiatrists and*  
536 *[say] "You have all the money we get for mental health, and you just sort out*  
537 *everything" ...protectionism gets in the way of better care." (MDP-04)*

538 Some respondents felt influence of patient groups and political targets could skew resource  
539 allocation:

540 *"When... you're taking a massive stack of antipsychotics, with all the negative impact*  
541 *that has on motivation.... those patients are the ones that I feel are most neglected*  
542 *by mental health services... the patient groups that talk the loudest, are [those] who*  
543 *we perhaps have the least value to offer...the patient groups who have the smallest*  
544 *voice... need the most attention." (PSY-07)*

545 MDPs felt frustrated attempts to address APM overprescribing did not result in savings to  
546 reinvest in services such as psychology:

547 *"Prescribing budgets are held in a different part of the [NHS organisation] ... I can't*  
548 *get hold of prescribing budgets, even if I've saved on one element of them to reinvest*  
549 *the savings." (MDP-06)*

550 Many respondents felt that contractual divisions between primary and secondary care  
551 created barriers, for example around ability to refer to weight management clinics being  
552 restricted to primary care, and service commissioners and providers needed to facilitate  
553 pathways that allowed ease of referral for interventions from all HCPs. Others felt that there  
554 was a need for more joint working between Royal Colleges, the British Medical Association  
555 and service providers to identify gaps in holistic provision and the need to alter the funding

556 mechanisms to overcome these. Many HCPs highlighted that APM prescribing should  
557 indicate ongoing monitoring, rather than specific SMI diagnoses, as currently occurred in the  
558 QOF mental health register:

559 *"I think the Royal colleges and others come together really well on single pieces of*  
560 *work, but actually our chances of getting the Academy of Royal Colleges to say,*  
561 *"Primary care is the way forward. Disinvest from all your fancy hospital services and*  
562 *spend the money where they make the biggest difference", there is zero chance, even*  
563 *though every leader in the Academy of Royal Colleges can intellectually appreciate*  
564 *the benefit."* (MDP04)

565

#### 566 **(b) Worsening inequality driving antipsychotic use**

567 Respondents often felt antipsychotic use was a 'stop-gap' to deal with consequences of  
568 socioeconomic inequality and the medicalisation of distress, which health services could not  
569 address directly, and the patient primarily needed social interventions regarding finances,  
570 housing, or education:

571 *"We go at stuff from the health level view. ...Until we're able to deal with the fact*  
572 *[people] can't feed their kids, or heat their homes, that schools don't have the*  
573 *resources to put into troubled young people. [antipsychotic prescribing] is not going*  
574 *to reduce in our medicalized society... I can absolutely see why [antipsychotic*  
575 *prescribing] rates are rising."* (MDP-04)

576 Another common area of concern was around pressure from relatives and care home staff  
577 to prescribe APMs to manage challenging behaviours in older adults with dementia, and felt

578 this was largely down to inadequate training, retention and recruitment of carer staff who  
579 have the skills to manage patients with behavioural difficulties using non-pharmacological  
580 methods. Many respondents felt powerless to address the wider socioeconomic  
581 determinants driving increasing mental distress in the community but recognised that this  
582 had to be addressed as a political priority that encompassed services beyond health. A  
583 number however felt that investment in better training and retention of skilled care home  
584 staff would reduce APM prescribing in elderly patients:

585 *“So, for example, care homes are running on empty. They don't have people who are*  
586 *skilled.... they have token specialist dementia champions, but they just don't have the*  
587 *resources to sit with people while their anxiety levels reduce, or engage them with*  
588 *memory rooms, and things that we know improve or reduce the need for*  
589 *antipsychotic use.” (GP-04)*

590

### 591 **(c) Medicolegal and regulatory fears of HCPs**

592 HCPs mentioned fears around stopping APMs if a patient subsequently harmed themselves  
593 or others; some felt they ‘prescribe to be seen to do something’ due to working in an  
594 unforgiving regulatory culture:

595 *“If I was to stop an antipsychotic...if something adverse happened, I think I would*  
596 *have a very difficult time justifying that action, even if it's a relatively safe thing to*  
597 *[do]... those things lead to medication overprescribing... even if it's the wrong thing*  
598 *to do, it's almost a sense that having done something is better than doing nothing.”*  
599 (GP-04)

600 Psychiatrists reported unrealistic societal expectations that an adverse outcome must

601 ‘always be someone’s fault’ which inhibited their willingness to deprescribe:

602 *“Physicians accept that there's a certain percentage of COPD patients who will die,*

603 *that it doesn't matter much resource you use...they will get worse, and some of those*

604 *people will die. And then there is a very marked reluctance... [within society] to*

605 *accept that [psychiatric] conditions also have a morbidity and mortality... which I find*

606 *frustrating.” (PSY-07)*

607 Many respondents felt that, at times, a degree of over-regulation created barriers, in that it

608 inhibited ability to devise appropriate care pathways and encouraged defensive clinical

609 practice. They mentioned that the regulators did not seem to recognise that this stifled

610 ability to innovate at times and did not seem to recognise that overzealous regulation could

611 paradoxically lead to indirect patient harm, and so wanted a debate around the culture in

612 which they had to practice.

613 One final unintended consequence of overzealous performance management that appeared

614 to contribute to increased APM use was around prescribing indicators for benzodiazepines

615 being closely monitored by national medicines management teams, with targets being to

616 achieve a reduction in their use. As a result, this was often given as feedback to clinicians in

617 quarterly reports on their prescribing activity, and many felt unfairly scrutinised as a result.

618 Some practitioners thus ‘gamed they system’ by switching to using sedating APMs (e.g.,

619 quetiapine) to treat insomnia rather than using benzodiazepines, as this was not monitored

620 at the national level, and thus some MDPs suggested that the wider use of off-licence APM

621 needed to be monitored also:

622 *“I'm guessing if we use diazepam as an example - diazepam was the elixir for*  
623 *everything. And we had, going back, a massive uptake in the prescription of*  
624 *diazepam. We are aware of the issue of diazepam now has, in a sense of its*  
625 *addiction... so we just turn to other medication with a similar effect; in this case it is*  
626 *antipsychotics.” (PSY-04)*

627

## 628 **DISCUSSION**

### 629 **Summary**

630 Our research shows how HCPs and MDPs reported competency gaps that impaired HCP  
631 ability to manage the varied mental and physical health needs of patients' prescribed APMs  
632 appropriately. Stakeholders suggested that deficiencies in postgraduate experience and  
633 professional development contributed to GPs and psychiatrists' lack of confidence to  
634 manage both the mental health and physical health aspects of APM management. Lack of  
635 postgraduate GP experience for psychiatrists inhibited their understanding of GP  
636 competences. Communication barriers, lack of integrated care records, limited resources,  
637 particularly in relation to psychology provision, and perceived pressures to move patient  
638 care back to GPs ultimately resulted in patients in primary care being 'trapped' on APM,  
639 inhibiting opportunities to deprescribe, and increasing cardiometabolic risk in the longer  
640 term. Organisational and contractual barriers between services exacerbated risks, with  
641 socioeconomic deprivation driving overprescribing. Both GPs and psychiatrists voiced  
642 professional fears of being blamed if an event causing harm occurred after stopping an  
643 APM, which inhibited deprescribing confidence. Many respondents had low expectations of  
644 patients with SMI, which also contributed to care deficiencies. These factors act at several

645 points in the care pathway and contribute to the increasing prevalence of APM use and  
646 accretion of cardiometabolic risk in this patient group in primary care (Figure 1).

647

648 **Figure 1: Pathway of patient care on antipsychotics and barriers to better integrated care**

649 **[insert Figure 1]**

650

### 651 **Strengths and Limitations**

652 This study examines reasons for increasing APM prevalence in primary care. We had input  
653 from team members from different professions (medicine, pharmacy, health research),  
654 medical specialities (general practice, psychiatry, clinical pharmacology, public health) and  
655 the study sought views of those managing services, helping shape mental health policy and  
656 contractual arrangements, and involved in postgraduate training. We recruited participants  
657 from across three UK nations, to minimise bias that might result from one health region.  
658 Data saturation was achieved. However, participation, which was voluntary, may mean  
659 participants had a particular interest in the problem, and we may not have acquired views of  
660 less interested clinicians, so there is a risk of recruitment bias. Finally, this is a qualitative  
661 study that identifies perceived issues of concern in relation to APM management, but it  
662 does not provide information about the relative importance of the different themes  
663 identified. Also, the work is undertaken in the UK, and while there may be similarities with  
664 other high-income countries there will also be differences worthy of exploration to better  
665 understand common international issues. Finally, this study does not seek the views of



666 patients who are prescribed APM and managed solely in primary care; a separate qualitative  
667 study examining this is currently underway.

668

### 669 **Comparison with existing literature**

670 This is the first study to examine management of APM for patients discharged to primary  
671 care, which makes comparisons difficult, but other studies partially consider this. Nash *et al*  
672 [20] examined decision-making around APM switching by psychiatrists and GPs in one  
673 health region in England but did not specifically consider patients managed solely in primary  
674 care. This work and other studies conducted with patients and professionals in the  
675 Netherlands reported similar themes: concerns around jeopardising mental health by  
676 switching APMs to reduce cardiometabolic risk was mentioned as a reason not to do so ,  
677 poor engagement with patients to make informed decisions, and diffusion of responsibility  
678 with respect to managing cardiometabolic risks secondary to APM use [5, 20]. Several  
679 studies in the UK, Netherlands and Canada confirm difficulties in communication and  
680 collaboration between primary and secondary care inhibits integrated care for people  
681 taking APM [20, 28-31]. Moncrieff *et al* examined patient and HCP factors acting as barriers  
682 to deprescribing of APM in the UK [32] and reported concerns about relapse and potential  
683 harms to the patient, but this did not elucidate concerns of the HCPs around medicolegal or  
684 regulatory risks to their professional role. Our data confirms these findings, and extend  
685 them, showing that factors including HCP training, contractual, organisational, and  
686 medicolegal factors also act as barriers to better person-centred care in the UK.

687

688 **Implications for future research and clinical practice**

689 Our findings suggest several practical actions policymakers and practitioners can take now  
690 to improve person-centred care for people on APM, which we summarise in Figure 2:

691

692 **Figure 2: Potential actions to improve integrated care for patients taking antipsychotics**  
693 **discharged to primary care**

694 **[insert figure 2]**

695

696 This will require action at several organisational levels, including changes to postgraduate  
697 curriculum design for both general practice and psychiatry, evidence-based guidance on  
698 APM prescribing duration in non-psychotic illness, greater investment in non-  
699 pharmacological resources and input from professional regulators to address HCP fears  
700 around a ‘blame culture’ that exists currently. Our analysis suggests that addressing  
701 competency gaps and communication barriers between primary and secondary care are  
702 those which are likely most amenable to change locally within health service organisations.  
703 Implementing structured discharge letters and mandatory use of shared care protocols are  
704 relatively easy to implement to improve integrated care of patients taking APM. Psychiatric  
705 inpatients usually have considerable physical health data collated during admission that  
706 allows accurate quantification of cardiovascular disease risk, but these are not always acted  
707 on by psychiatric teams; training to ensure appropriate pharmacological interventions are  
708 undertaken is needed [33]. Modification of care pathways for non-pharmacological  
709 interventions to allow referral by mental health staff, regular reviews by competent HCPs

710 able to optimise or withdraw APM, and appointment of staff to provide support to patients  
711 that is non-pharmacological may be harder to achieve. Particular challenges exist in terms of  
712 capacity in terms of psychological provision, but also within in the social care sector with  
713 staff capable of managing behavioural consequences of dementia without recourse to APM  
714 use. The wider societal factors, around attitudes towards patients with SMI and dealing with  
715 socioeconomic factors increasing mental distress are beyond local action and require a co-  
716 ordinated national approach. It is also clear that well-intentioned performance management  
717 and regulation may paradoxically contribute to increasing prevalence of patients on APM in  
718 primary care. HCPs increasingly use APM as an alternative to benzodiazepine use for  
719 insomnia and anxiety, due to the latter being closely monitored as a quality prescribing  
720 indicator in some regions; medicines management teams should consider the wider use of  
721 APM for non-psychotic illness in their performance indicators. The wider regulatory milieu in  
722 which HCPs perceive they are working is leading to defensive practice, where patients are  
723 left on APM due to fear of professional censure should a catastrophic adverse event occur if  
724 HCPs reduce or withdraw the medication. Regulators need to reassure HCPs that this is  
725 unlikely to occur, as this was a common concern for HCPs; a national debate on this is  
726 required.

727 Further research is required to explore experiences of patients prescribed APMs discharged  
728 to primary care, and to examine if similar barriers to person-centred, integrated care exist  
729 internationally in other health systems where primary and secondary care operate in an  
730 analogous manner to the UK (e.g., Australia, New Zealand, Ireland, Canada). Studies have  
731 examined attitudes of patients taking antipsychotics regarding their management and  
732 physical health [30], but none formally examined the growing proportion of patients

733 prescribed APM no longer under psychiatric review. Further study is needed of clinical and  
734 postgraduate educational policies in the UK and elsewhere that have contributed to  
735 fragmented services with HCPs, particularly in secondary care having inadequate  
736 understanding of the primary care context. The theme of regulatory fear is also evident in  
737 HCPs treating patients with SMI and acts as a barrier to deprescribing of APM. This needs  
738 further exploration internationally, with regulators, patients, and HCPs together – to  
739 consider how the regulatory and performance management ‘observer effect’ may impair or  
740 distort clinical practice.

741

## 742 **CONCLUSIONS**

743 There is considerable risk that the increasing use of APM in society is inadequately  
744 managed. Unless we address the factors that contribute to fragmented and suboptimal care  
745 for those taking APM, poor long-term outcomes in terms of increased rates of  
746 cardiometabolic disease will be difficult to ameliorate. The theme of regulatory fear by HCPs  
747 is a new factor emerging as a barrier to deprescribing of APM, and this needs further  
748 examination in other studies to determine if this is an international concern. Many changes  
749 could easily be made to improve person-centred, integrated care of those on APM with  
750 minimal need for change by health service organisations. However, other issues such as  
751 inadequate availability of non-pharmacological alternatives to APM and socioeconomic  
752 factors increasing mental distress will require national leadership by key stakeholders to  
753 improve the current situation.

754

755 **Acknowledgements:** We thank the generous input of the participants who took part in the  
756 interviews.

757 **Contributors:** AW, FM, SS, IB and LW conceived the study and wrote the application for  
758 funding and the protocol. PS provided public perspective on the study design and results.  
759 AW conducted the data collection. AW, AA, SW and LW undertook the primary coding and  
760 thematic analysis, and all other authors (PA, FM, SS, DJ, IB) contributed to the data analysis  
761 and discussion. AW and LW drafted the manuscript, and all authors commented on the  
762 manuscript.

763 **Funding:** This work was funded by a Research Time Award to AW from Health and Care  
764 Research Wales (NHS-RTA-21-02).

765 **Competing interests:** None declared.

766 **Consent for Publication:** Not Required.

767 **Ethical Approval and Governance:** The study received ethical approval from the Health  
768 Research Authority (IRAS: 311503) via NHS Research Ethics Committee-06 (22/WA/0173).

769 **Provenance and Peer Review:** Not commissioned; externally peer reviewed.

770 **Data availability statement:** Data are available from the corresponding author on  
771 reasonable request.

772 **Supplemental material:** Study protocol, semi structured interviews template, additional  
773 quotes.

774 **Open access:** Put in relevant licence.

775

## 776 REFERENCES

- 777 1. Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar  
778 disorder and schizophrenia: UK-based cohort study 2000-2014. *Br J Psychiatry*, 2017. 211(3):  
779 175-181. Pubmed PMID: 28684403
- 780 2. John A, McGregor J, Jones I, Lee SC, Walters JTR, Owen MJ et al. Premature mortality among  
781 people with severe mental illness - New evidence from linked primary care data. *Schizophr*  
782 *Res*, 2018. 199: 154-162. Pubmed PMID: 29728293
- 783 3. Walker, ER., McGee RE, Druss BG. Mortality in Mental Disorders and Global Disease Burden  
784 Implications: A Systematic Review and Meta-analysis. *JAMA Psychiatry*, 2015. 72(4): 334-  
785 341. Pubmed PMID: 25671328
- 786 4. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among  
787 patients admitted with major psychiatric disorders: a register-based study comparing  
788 mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder,  
789 and schizophrenia. *J Clin Psychiatry*, 2007. 68(6): 899-907. Pubmed PMID: 17592915
- 790 5. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse  
791 effects associated with antipsychotic drugs. *Nat Rev Endocrinol*, 2011. 8(2): 114-26. Pubmed  
792 PMID: 22009159
- 793 6. Roberts R, Neasham A, Lambrinudi C, Khan A. A quantitative analysis of antipsychotic  
794 prescribing trends for the treatment of schizophrenia in England and Wales. *JRSM Open*,  
795 2018. 9(4): 2054270418758570. Pubmed PMID: 29707225
- 796 7. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or  
797 cardiometabolic risk? *Acta Psychiatr Scand*, 2009. 119(3): 171-179. Pubmed PMID:  
798 19178394
- 799 8. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and  
800 clinical implications. *CNS Drugs*, 2007. 21(11): 911-36. Pubmed PMID: 17927296
- 801 9. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and  
802 sudden death. *Drugs*, 2002. 62(11): 1649-71. Pubmed PMID: 12109926
- 803 10. Mwebe H, Volante M, Weaver T. Monitoring cardiovascular disease risk in individuals with  
804 severe mental illness in an inpatient mental health setting: a secondary data analysis. *Br J*  
805 *Card Nurs*, 2020. 9(3): 1-14. doi.org/10.12968/bjca.2020.0157
- 806 11. Hardoon S, Hayes J, Viding E, McCrory E, Walters K, Osborn D. Prescribing of antipsychotics  
807 among people with recorded personality disorder in primary care: a retrospective  
808 nationwide cohort study using The Health Improvement Network primary care database.  
809 *BMJ Open*, 2022. 12(3): e053943. Pubmed PMID: 35264346
- 810 12. Gerhard T, Stroup TS, Correll CU, Huang C, Tan Z, Crystal S et al. Antipsychotic Medication  
811 Treatment Patterns in Adult Depression. *J Clin Psychiatry*, 2018. 79(2). Pubmed PMID:  
812 28686818
- 813 13. Comer JS, Mojtabai R, Olfson M. National Trends in the Antipsychotic Treatment of  
814 Psychiatric Outpatients With Anxiety Disorders. *Am J Psychiatry*, 2011. 168(10): 1057-1065.  
815 Pubmed PMID: 21799067
- 816 14. Khaledi-Paveh B, Maazinezhad S, Rezaie L, Khazaie H. Treatment of chronic insomnia with  
817 atypical antipsychotics: results from a follow-up study. *Sleep Sci*, 2021. 14(1): 27-32.  
818 Pubmed PMID: 34104334
- 819 15. Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a  
820 systematic review of benefits and risks from meta-analyses. *Ther Adv Chronic Dis*, 2016.  
821 7(5): 229-45. Pubmed PMID: 27583123
- 822 16. Alexander RT, Shankar R, Cooper SA, Bhaumik S, Hastings R, Kapugama CL et al., Challenges  
823 and pitfalls of antipsychotic prescribing in people with learning disability. *Br J Gen Pract*,  
824 2017. 67(661): 372-373. Pubmed PMID: 28751349

- 825 17. Posey DJ, Stigler KA, Erikson CA, McDouble CJ. Antipsychotics in the treatment of autism. *J*  
826 *Clin Invest*, 2008. 118(1): 6-14. Pubmed PMID: 18172517
- 827 18. Psychoses and related disorders. In: Joint Formulary Committee, British National Formulary  
828 [internet]. London: British Medical Association and Royal Pharmaceutical Society of Great  
829 Britain; [cited 2023 Oct 23]. Available from: [https://bnf.nice.org.uk/treatment-](https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders/)  
830 [summaries/psychoses-and-related-disorders/](https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders/)
- 831 19. Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of antipsychotics and  
832 antidepressants in general practice and specialist care in Norway. *Acta Psychiatr Scand*,  
833 2011. 123(6): 459-465. Pubmed PMID: 21401533
- 834 20. Nash A, Kingstone T, Farooq S, Tunmore J, Chew-Graham CA. Switching antipsychotics to  
835 support the physical health of people with severe mental illness: a qualitative study of  
836 healthcare professionals' perspectives. *BMJ Open*, 2021. 11(2): e042497. Pubmed PMID:  
837 33637542
- 838 21. Woodall A. Managing patients on atypical antipsychotics in primary care. *Prescriber*, 2021.  
839 32(11-12): 18-23. doi.org/10.1002/psb.1952
- 840 22. Nicaise P, Giacoo D, Soltmann B, Pfennig A, Miglietta E, Lasalvia A et al. Healthcare system  
841 performance in continuity of care for patients with severe mental illness: A comparison of  
842 five European countries. *Health Policy*, 2020. 124(1): 25-36. Pubmed PMID: 31831211
- 843 23. Marston L, Nazareth I, Petersen I, Walters K, Osborn DP. Prescribing of antipsychotics in UK  
844 primary care: a cohort study. *BMJ Open*, 2014. 4(12): e006135. Pubmed PMID: 25524544
- 845 24. Reilly S, Planner C, Hann M, Reeves D, Nazareth I, Lester H. The role of primary care in  
846 service provision for people with severe mental illness in the United Kingdom. *PLoS One*,  
847 2012. 7(5): e36468. Pubmed PMID: 22615769
- 848 25. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research  
849 (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*, 2007.  
850 19(6): 349-357. Pubmed PMID: 17872937
- 851 26. Braun V, Clark V. Using thematic analysis in psychology. *Qual Res Psychol*, 2006. 3(2): 77-  
852 101. doi.org/10.1191/1478088706qp063oa
- 853 27. Consultantconnect.org.uk [internet]. Oxford UK; c2023 [cited 2023 Oct 23]. Available from:  
854 <https://www.consultantconnect.org.uk/>.
- 855 28. Kozłowska O, Lumb A, Tan GD, Rea R. Barriers and facilitators to integrating primary and  
856 specialist healthcare in the United Kingdom: a narrative literature review. *Future Healthc J*,  
857 2018. 5(1): 64-80. Pubmed PMID: 31098535
- 858 29. Ross LE, Vlgod S, Wishart J, Waese M, Spence JD, Oliver J et al., Barriers and facilitators to  
859 primary care for people with mental health and/or substance use issues: a qualitative study.  
860 *BMC Fam Pract*, 2015. 16: 135. Pubmed PMID: 26463083
- 861 30. van Hasselt FM, Oud MJ, Loonen AJ. Improvement of care for the physical health of patients  
862 with severe mental illness: a qualitative study assessing the view of patients and families.  
863 *BMC Health Serv Res*, 2013. 13: 426. Pubmed PMID: 24144438
- 864 31. van Hasselt FM, Oud MJ, Loonen AJ. Practical recommendations for improvement of the  
865 physical health care of patients with severe mental illness. *Acta Psychiatr Scand*, 2015.  
866 131(5): 387-96. Pubmed PMID: 25495118
- 867 32. Moncrieff JS, Gupta S, M.A. Horowitz MA, Barriers to stopping neuroleptic (antipsychotic)  
868 treatment in people with schizophrenia, psychosis or bipolar disorder. *Ther Adv*  
869 *Psychopharmacol*, 2020. 10: 2045125320937910. Pubmed PMID: 32670542
- 870 33. Woodall A, Prosser A, Griffiths M, Shooter B, Garfitt J, Walker L, Buchan I. Cardiovascular risk  
871 estimation in rural psychiatric inpatient populations: Cross-sectional preliminary study.  
872 *Psychiatry Res Commun*, 2023. 3(1): 100103. Pubmed PMID: 37654699

873

**Figure 1: Pathway of patient care on antipsychotics and barriers to better integrated care**




Figure showing barriers to care



Theme	Sub-theme	Problem	Action possible now?	Suggested solution	Action to achieve by:
Confidence of HCPs around holistic management of APM	GPs reluctant to manage APM without psychiatrist support	GPs Lack confidence to trial APM optimisation	Yes	Structured letters* from psychiatrists give clear advice on indication, duration, switching, and dose of APMs before discharge, and confirm discussion with patient.	Directors of Mental Health services
	Psychiatrists reluctant to address cardiometabolic risk	Psychiatrists not addressing physical health risk	Yes	Support for psychiatrists: Employment of GPs in advisory roles to support cardiometabolic interventions while under psychiatric care. Support staff to co-ordinate physical health monitoring and interventions	Directors of Mental Health services
	Gaps for HCP in postgraduate and post-speciality training	Training does not cover the full range of skills to provide holistic care	No	Co-ordination of postgraduate curriculum design by Royal College of General Practitioners and Royal College of Psychiatrists Mandatory primary care experience in postgraduate training for all psychiatry trainees.	National priority setting by Royal Colleges
Service pressures 'trapping' patients on antipsychotics in primary care	Limited psychology provision	Lack of psychology driving APM use	No	Employ clinical associates in applied psychology to increase psychological therapy capacity. Savings in psychotropic medication use earmarked for investment in psychological provision.	Accountable officer of health providers; Directors of Mental Health services
	Pressure to discharge patients to primary care	Limited psychiatric appointment resource	No	Formal shared care agreements for antipsychotics before a patient can be discharged to primary care with mandated plan on future cessation and withdrawal.	National priority setting
	Difficulty to get psychiatric review for patients with cardiometabolic risks	Limited psychiatric appointment resource	No	Formal shared care agreements to include a 5 yearly mandated review by psychiatrist to determine if ongoing antipsychotic use is needed. Train pharmacists to proactively address cardiometabolic risk in pharmacy and GP settings	National priority setting
Communication barriers between primary and secondary care	Inadequate information in written handover	Inadequate advice in discharge letters to GPs	Yes	Structured letters* (see above).	Directors of Mental Health services
	Difficulties in verbal communication between primary and secondary care	Barriers to verbal communication	Partly	Direct telephone lines to "duty medical professional"; use of alternative communication (e.g., Microsoft Teams) to make contact easier.	Directors of IT, Mental Health services, Primary Care

	Poor integration of IT systems used in health services	Inadequate access to care records	Partly	Ensure all clinicians have a minimum of 'read access' to summary care records (GP and mental health records) Adoption of a common electronic health record system across the primary and secondary care estate with shared read-write access.	Directors of IT
HCPs have low expectations of patients taking APM	Low expectations included feeling patients won't engage, are not motivated, and discriminatory risks	Attitudes of HCPs	Partly	Challenge attitudes and look at different ways to engage patients with SMI which reduce inequality of access to care	Directors of mental health services and primary care; National priority setting
Strategic factors affecting APM prescribing in primary care	Contractual divisions between primary and secondary care	QOF registers inadequate	Partly	Ensure each GP practice has register of patients on antipsychotics with performance management of monitoring and use by commissioners of services	Directors of primary care; National priority setting
	Worsening inequality driving antipsychotic use	Socioeconomic deprivation causing distress	No	Redistribution of resources to improve mental health resilience.	National priority setting
	Medicolegal and regulator fears by HCPs.	HCP fear of censure	Partly	Regulators to reassure healthcare professionals; set up a joint committee to investigate and report on unintended harms of the regulatory environment impacting on psychiatric patient care. Consider use of antipsychotics in non-SMI illness for prescribing performance indicators.	National priority setting; Medicines management teams